Souhaitez-vous accéder aux communiqués récents ?
Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.
-
WALTHAM, Mass., Jan. 04, 2018 (GLOBE NEWSWIRE) -- Eloxx Pharmaceuticals, Inc. (“Eloxx”) (OTC:SVOND), a clinical-stage biopharmaceutical company developing novel small molecule medicines to treat...
-
Biopharmaceutical Industry Leader with Extensive Experience In Drug Development, Strategic Business Combinations and Commercialization to Lead The Company’s Strategy, Vision and Execution WALTHAM,...
-
Biopharmaceutical Industry Leader with Extensive Experience In Drug Development, Strategic Business Combinations and Commercialization to Lead The Company’s Strategy, Vision and Execution WALTHAM,...
-
Company to focus on advancing the clinical development of ELX-02, a disease-modifying therapy for genetic diseases caused by nonsense mutations WALTHAM, Mass., REHOVOT, Israel, and SAN DIEGO, Dec. ...
-
WALTHAM, Mass. and REHOVOT, Israel and SAN DIEGO, Dec. 20, 2017 (GLOBE NEWSWIRE) -- Eloxx Pharmaceuticals Ltd. (“Eloxx”) and Sevion Therapeutics, Inc. (OTCQB:SVON) (“Sevion”) today announced the two...
-
Lead molecule targets genetic nonsense mutation in rare diseases Dose escalating study to enroll 36 subjects Data expected in the fourth quarter of 2018 SAN DIEGO and REHOVOT, Israel and BOSTON,...